Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Khr Biotec GmbH has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, while THOMAE, EVAN GODFREY is the busiest examiner with 1 pending action.
The two matters are distributed across separate examination channels. Counsel should maintain a consistent biotechnology position where appropriate, but prepare responses that reflect each examiner’s and art unit’s distinct context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THOMAE, EVAN GODFREY | 1 | — | — |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18874166 | NOVEL RAS INHIBITORS | THOMAE, EVAN GODFREY | — |
| 18865113 | MITOXANTHRONE DERIVATIVES AS RAS INHIBITORS | ARCORIA, PAUL JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874166 | NOVEL RAS INHIBITORS | THOMAE, EVAN GODFREY | 1623 | §103§112 | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18865113 | MITOXANTHRONE DERIVATIVES AS RAS INHIBITORS | ARCORIA, PAUL JOSEPH | 1621 | §102§103§112 | Non-Final OA | — | Pending | Nov 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKhr Biotec GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Evan Godfrey Thomae has the most, with 1 of Khr Biotec GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
